Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of “Moderate Buy” by Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been assigned an average recommendation of “Moderate Buy” from the eighteen analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and sixteen have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $72.2941.

Several equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, February 3rd. Wells Fargo & Company lowered their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday, December 30th. Barclays reduced their price target on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a research report on Monday, November 24th. Jefferies Financial Group decreased their price target on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a report on Tuesday, December 30th. Finally, Leerink Partners dropped their price objective on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th.

Insider Buying and Selling

In related news, CFO Howard Horn sold 3,061 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $23.56, for a total value of $72,117.16. Following the completion of the transaction, the chief financial officer owned 88,935 shares in the company, valued at $2,095,308.60. This represents a 3.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 6,227 shares of company stock valued at $187,126. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently made changes to their positions in the business. HRT Financial LP acquired a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $11,538,000. SR One Capital Management LP purchased a new position in Ultragenyx Pharmaceutical in the 4th quarter worth about $3,168,000. State Board of Administration of Florida Retirement System raised its holdings in Ultragenyx Pharmaceutical by 4.4% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 96,836 shares of the biopharmaceutical company’s stock worth $2,227,000 after buying an additional 4,070 shares during the period. Renaissance Technologies LLC lifted its stake in Ultragenyx Pharmaceutical by 1,571.7% during the fourth quarter. Renaissance Technologies LLC now owns 366,100 shares of the biopharmaceutical company’s stock valued at $8,420,000 after buying an additional 344,200 shares in the last quarter. Finally, Ensign Peak Advisors Inc lifted its stake in Ultragenyx Pharmaceutical by 41.2% during the fourth quarter. Ensign Peak Advisors Inc now owns 250,571 shares of the biopharmaceutical company’s stock valued at $5,763,000 after buying an additional 73,150 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Q4 revenue and product momentum: Ultragenyx reported Q4 revenue of $207M (up ~25.5% YoY) and full‑year 2025 revenue of $673M; Crysvita® and Dojolvi® remain the primary revenue drivers. These topline figures beat some analyst revenue estimates and show continued commercial growth. Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Q4 EPS roughly in line: Reported EPS was a (-$1.29) loss — close to consensus (sources vary slightly on the exact consensus), and management held the scheduled earnings call/press release where they discussed results and pipeline progress. Investors can review the call/PR for color on commercialization and development milestones. Earnings Transcript / Press Release
• Negative Sentiment: FY‑2026 revenue guidance below Street: Ultragenyx set FY‑2026 revenue guidance of about $730M–$760M, below the consensus (~$785M), creating downward earnings/valuation pressure as investors re‑model growth expectations. Guidance & Corporate Update
• Negative Sentiment: Multiple securities‑fraud class actions / law‑firm notices: Several firms have filed notices or are soliciting lead plaintiffs alleging misstatements related to the company’s drug (setrusumab) and disclosures covering Aug 3, 2023–Dec 26, 2025. Litigation risk and potential legal costs create uncertainty and often weigh on biotech stocks. Investor Alert — Class Action Filed
• Negative Sentiment: Profitability and outlook remain challenged: Ultragenyx still shows wide negative margins and negative ROE; consensus expects materially negative FY EPS, keeping valuation dependent on future commercial execution and pipeline readouts. Market Data & Ratios

Ultragenyx Pharmaceutical Trading Down 1.6%

NASDAQ:RARE opened at $23.50 on Friday. The firm’s fifty day simple moving average is $27.23 and its 200 day simple moving average is $29.78. Ultragenyx Pharmaceutical has a twelve month low of $18.41 and a twelve month high of $46.27. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of -3.96 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, beating the consensus estimate of ($1.30) by $0.01. The business had revenue of $207.00 million during the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 91.95% and a negative return on equity of 414.17%. The business’s quarterly revenue was up 25.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.39) earnings per share. On average, analysts predict that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.